GCP
PETX

GSA Capital Partners’s Aratana Therapeutics, Inc. PETX Stock Holding History

GSA Capital Partners’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-36,487
Closed -$224K – 1838
2018
Q4 		$224K Buy
+36,487
New +$223K 0.03% 1032
2016
Q4 		– Sell
-31,038
Closed -$291K – 2065
2016
Q3 		$291K Buy
+31,038
New +$258K 0.02% 1392

Other funds holding PETX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
GPGA
Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return
Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $14.3B AUM 19.8% 1-Year Est. Return

GSA Capital Partners's PETX Position: Q1 2019 in Review

GSA Capital Partners sold out of Aratana Therapeutics, Inc. (PETX) in Q1 2019, closing a stake of 36,487 shares — an estimated $224K sold.

GSA Capital Partners first reported a position in PETX in Q3 2016 and held it in 2 quarters. The position peaked at $291K in Q3 2016. 104 funds tracked by Wall St. Rank hold PETX as of Q1 2019.

  • GSA Capital Partners reported no remaining Aratana Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
  • GSA Capital Partners sold 36,487 Aratana Therapeutics, Inc. shares in Q1 2019, an estimated $224K.
  • GSA Capital Partners first reported a position in Aratana Therapeutics, Inc. in Q3 2016 and held it in 2 quarters.
  • GSA Capital Partners's Aratana Therapeutics, Inc. position peaked at $291K in Q3 2016.
  • 104 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q1 2019.

Based on GSA Capital Partners's 13F filing for Q1 2019, filed 15 May 2019.